rasagiline

monoamine oxidase B ; Rattus norvegicus







41 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34679739 Melatonin Analogues Potently Inhibit MAO-B and Protect PC12 Cells against Oxidative Stress. 2021 Oct 12 1
2 34679775 Highly Potent, Selective, and Competitive Indole-Based MAO-B Inhibitors Protect PC12 Cells against 6-Hydroxydopamine- and Rotenone-Induced Oxidative Stress. 2021 Oct 19 1
3 32086070 Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease. 2020 May 1 3
4 29956417 Rasagiline, an inhibitor of MAO-B, decreases colonic motility through elevating colonic dopamine content. 2018 Nov 3
5 26530401 Pharmacokinetic interaction study between flavanones (hesperetin, naringenin) and rasagiline mesylate in wistar rats. 2016 1
6 27220335 3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells. 2016 Sep 1
7 27503749 A spectrophotometric assay for monoamine oxidase activity with 2, 4-dinitrophenylhydrazine as a derivatized reagent. 2016 Nov 1 1
8 24525144 Rasagiline prevents neurodegeneration in thiamine deficient rats-a longitudinal MRI study. 2014 Apr 4 1
9 22982254 Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway. 2013 Feb 2
10 20919927 Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease? 2011 Mar 1 2
11 21338509 Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro. 2011 Feb 21 1
12 20714170 Electropharmacograms of rasagiline, its metabolite aminoindan and selegiline in the freely moving rat. 2010 2
13 23908775 Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential. 2010 Jul 1
14 19396396 Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain. 2009 Nov 1
15 18771016 [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508]. 2008 Mar 1
16 17016505 Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat. 2006 Nov 1
17 17157368 L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action. 2006 Dec 1
18 15721173 Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells. 2005 Mar 1
19 15765264 Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model. 2005 Aug 1
20 14732458 Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. 2004 Jan 30 1
21 15144871 Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. 2004 Jun 1
22 15247150 Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. 2004 Sep 1
23 15339864 Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. 2004 Oct 2
24 12871751 Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens. 2003 Jul 11 1
25 14525944 The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. 2003 Dec 1
26 11779573 Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. 2002 Jan 11 1
27 12039419 Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. 2002 Mar 2
28 11159700 Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. 2001 Jan 4
29 11462767 Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. 2001 Jun 1
30 11716145 Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. 2001 1
31 12043833 Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. 2001 Dec 2
32 10993123 Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. 2000 Jun 23 1
33 11192605 The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. 2000 Dec 18 1
34 11205137 TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. 2000 1
35 10518120 Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. 1999 Nov 1 3
36 10907720 Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. 1999 2
37 9559942 Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. 1998 Mar 9 1
38 9564629 Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. 1998 1
39 9632221 Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. 1998 Jun 1
40 8988465 Pharmacology and neuroprotective properties of rasagiline. 1996 1
41 6793119 Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. 1981 May 1